Dopaminergic Inhibition of Catecholamine Secretion from Chromaffin Cells: Evidence that Inhibition Is Mediated by D4 and D5 Dopamine Receptors
: Previous studies have suggested that activation of D2‐like dopamine receptors inhibits catecholamine secretion from adrenal chromaffin cells. The purpose of this study was to determine whether the activation of D1‐like receptors on chromaffin cells affects either catecholamine release from the cel...
Gespeichert in:
Veröffentlicht in: | Journal of neurochemistry 1996-01, Vol.66 (1), p.222-232 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 232 |
---|---|
container_issue | 1 |
container_start_page | 222 |
container_title | Journal of neurochemistry |
container_volume | 66 |
creator | Dahmer, Mary K. Senogles, Susan E. |
description | : Previous studies have suggested that activation of D2‐like dopamine receptors inhibits catecholamine secretion from adrenal chromaffin cells. The purpose of this study was to determine whether the activation of D1‐like receptors on chromaffin cells affects either catecholamine release from the cells or the inhibition of secretion by D2‐like dopamine receptors. Both D1‐ and D2‐selective agonists inhibited secretion elicited by dimethylphenylpiperazinium (DMPP), veratridine, and high K+ levels. The D1‐selective agonists 6‐chloro‐7,8‐dihydroxy‐3‐allyl‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine (Cl‐APB) and SKF‐38393 inhibited DMPP‐stimulated catecholamine secretion in a concentration‐dependent manner; 50% inhibition was obtained with ∼10 µM Cl‐APB and ∼100 µM SKF‐38393. Of the D2‐selective agonists, bromocriptine was a more potent inhibitor of DMPP‐stimulated catecholamine release than was quinpirole. The inhibition of secretion caused by Cl‐APB or SKF‐38393 was additive with the inhibition caused by bromocriptine. Pertussis toxin treatment (50 ng/ml, 18 h) attenuated the inhibitory effect of D2‐selective, but not D1‐selective, dopamine agonists. In addition, forskolin‐stimulated adenylyl cyclase activity was inhibited by D2‐selective, but not D1‐selective, agonists. Neither D1‐ nor D2‐selective agonists stimulated adenylyl cyclase activity in the cells, although cyclase activity was stimulated by forskolin, carbachol, and vasoactive intestinal peptide. DMPP‐stimulated Ca2+ uptake was inhibited by both D1‐ and D2‐selective dopamine agonists. PCR analysis was used to determine which of the dopamine receptor subtypes within the D1‐like and D2‐like subfamilies was responsible for the observed inhibition. PCR analysis indicated that mRNA for only D4 and D5 dopamine receptor subtypes was present in chromaffin cells. These combined data suggest that D1‐ and D2‐selective agonists inhibit Ca2+ uptake and catecholamine secretion by activating D4 and D5 dopamine receptors on chromaffin cells. |
doi_str_mv | 10.1046/j.1471-4159.1996.66010222.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77924849</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17023992</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4402-23a1065cc046ec6f95fece0bed05d38318a0784199140908c58f34c6d288087c3</originalsourceid><addsrcrecordid>eNqVkV2PEyEUhonRrHX1J5iQaLyb8cAAA3plputas2rixzWhDFia-agw1e2f8DdLtx_xzpgQSM778h44D0LPCJQEmHi5LgmrScEIVyVRSpRCAAFKaXl7D83O2n00g1wtKmD0IXqU0hqACCbIBbqQnFLF5Qz9no8b04fBxe_B4sWwCsswhXHAo8eNmZxdjd2djr84G92d5OPY42aVd-N9GHDjui69wlc_Q-sG6_C0MtPfUYuEP7g25LQWL3d4zrAZWjzn-NQbf3bWbaYxpsfogTddck-O5yX69vbqa_OuuPl0vWje3BSWMaAFrQwBwa3N43BWeMV9ToCla4G3layINFBLlodDGCiQlktfMStaKiXI2laX6MUhdxPHH1uXJt2HZPM_zODGbdJ1rSiTTP3TSGqglVI0G18fjDaOKUXn9SaG3sSdJqD32PRa79HoPRq9x6ZP2PRtvv302Ga77F17vnvklPXnR90kazofzWBDOtuoEpTXJNuuD7ZfoXO7_3mBfv-xyetUqP4AKPG1KA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17023992</pqid></control><display><type>article</type><title>Dopaminergic Inhibition of Catecholamine Secretion from Chromaffin Cells: Evidence that Inhibition Is Mediated by D4 and D5 Dopamine Receptors</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Dahmer, Mary K. ; Senogles, Susan E.</creator><creatorcontrib>Dahmer, Mary K. ; Senogles, Susan E.</creatorcontrib><description>: Previous studies have suggested that activation of D2‐like dopamine receptors inhibits catecholamine secretion from adrenal chromaffin cells. The purpose of this study was to determine whether the activation of D1‐like receptors on chromaffin cells affects either catecholamine release from the cells or the inhibition of secretion by D2‐like dopamine receptors. Both D1‐ and D2‐selective agonists inhibited secretion elicited by dimethylphenylpiperazinium (DMPP), veratridine, and high K+ levels. The D1‐selective agonists 6‐chloro‐7,8‐dihydroxy‐3‐allyl‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine (Cl‐APB) and SKF‐38393 inhibited DMPP‐stimulated catecholamine secretion in a concentration‐dependent manner; 50% inhibition was obtained with ∼10 µM Cl‐APB and ∼100 µM SKF‐38393. Of the D2‐selective agonists, bromocriptine was a more potent inhibitor of DMPP‐stimulated catecholamine release than was quinpirole. The inhibition of secretion caused by Cl‐APB or SKF‐38393 was additive with the inhibition caused by bromocriptine. Pertussis toxin treatment (50 ng/ml, 18 h) attenuated the inhibitory effect of D2‐selective, but not D1‐selective, dopamine agonists. In addition, forskolin‐stimulated adenylyl cyclase activity was inhibited by D2‐selective, but not D1‐selective, agonists. Neither D1‐ nor D2‐selective agonists stimulated adenylyl cyclase activity in the cells, although cyclase activity was stimulated by forskolin, carbachol, and vasoactive intestinal peptide. DMPP‐stimulated Ca2+ uptake was inhibited by both D1‐ and D2‐selective dopamine agonists. PCR analysis was used to determine which of the dopamine receptor subtypes within the D1‐like and D2‐like subfamilies was responsible for the observed inhibition. PCR analysis indicated that mRNA for only D4 and D5 dopamine receptor subtypes was present in chromaffin cells. These combined data suggest that D1‐ and D2‐selective agonists inhibit Ca2+ uptake and catecholamine secretion by activating D4 and D5 dopamine receptors on chromaffin cells.</description><identifier>ISSN: 0022-3042</identifier><identifier>EISSN: 1471-4159</identifier><identifier>DOI: 10.1046/j.1471-4159.1996.66010222.x</identifier><identifier>PMID: 8522958</identifier><identifier>CODEN: JONRA9</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology ; Adenylate Cyclase Toxin ; Adenylyl cyclase ; Adenylyl Cyclases - metabolism ; Adrenal gland ; Adrenal Medulla - drug effects ; Adrenal Medulla - metabolism ; Adrenals. Interrenals ; Adrenomedullary hormones. Regulation ; Animals ; Base Sequence ; Benzazepines - pharmacology ; Biological and medical sciences ; Bromocriptine - pharmacology ; Ca2+ uptake ; Calcium - physiology ; Catecholamines - metabolism ; Cattle ; Cells, Cultured ; Colforsin - pharmacology ; Cyclic AMP - physiology ; Depression, Chemical ; Dimethylphenylpiperazinium Iodide - antagonists & inhibitors ; Dopamine - physiology ; Dopamine Agonists - pharmacology ; Fundamental and applied biological sciences. Psychology ; Molecular Sequence Data ; PCR ; Pertussis Toxin ; Polymerase Chain Reaction ; Potassium - antagonists & inhibitors ; Receptors, Dopamine - drug effects ; Receptors, Dopamine - genetics ; Receptors, Dopamine - physiology ; Receptors, Dopamine D1 - physiology ; Receptors, Dopamine D2 - physiology ; Receptors, Dopamine D4 ; Receptors, Dopamine D5 ; Second Messenger Systems - drug effects ; Veratridine - antagonists & inhibitors ; Vertebrates: endocrinology ; Virulence Factors, Bordetella - pharmacology</subject><ispartof>Journal of neurochemistry, 1996-01, Vol.66 (1), p.222-232</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4402-23a1065cc046ec6f95fece0bed05d38318a0784199140908c58f34c6d288087c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1471-4159.1996.66010222.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1471-4159.1996.66010222.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,4024,27923,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2962571$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8522958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dahmer, Mary K.</creatorcontrib><creatorcontrib>Senogles, Susan E.</creatorcontrib><title>Dopaminergic Inhibition of Catecholamine Secretion from Chromaffin Cells: Evidence that Inhibition Is Mediated by D4 and D5 Dopamine Receptors</title><title>Journal of neurochemistry</title><addtitle>J Neurochem</addtitle><description>: Previous studies have suggested that activation of D2‐like dopamine receptors inhibits catecholamine secretion from adrenal chromaffin cells. The purpose of this study was to determine whether the activation of D1‐like receptors on chromaffin cells affects either catecholamine release from the cells or the inhibition of secretion by D2‐like dopamine receptors. Both D1‐ and D2‐selective agonists inhibited secretion elicited by dimethylphenylpiperazinium (DMPP), veratridine, and high K+ levels. The D1‐selective agonists 6‐chloro‐7,8‐dihydroxy‐3‐allyl‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine (Cl‐APB) and SKF‐38393 inhibited DMPP‐stimulated catecholamine secretion in a concentration‐dependent manner; 50% inhibition was obtained with ∼10 µM Cl‐APB and ∼100 µM SKF‐38393. Of the D2‐selective agonists, bromocriptine was a more potent inhibitor of DMPP‐stimulated catecholamine release than was quinpirole. The inhibition of secretion caused by Cl‐APB or SKF‐38393 was additive with the inhibition caused by bromocriptine. Pertussis toxin treatment (50 ng/ml, 18 h) attenuated the inhibitory effect of D2‐selective, but not D1‐selective, dopamine agonists. In addition, forskolin‐stimulated adenylyl cyclase activity was inhibited by D2‐selective, but not D1‐selective, agonists. Neither D1‐ nor D2‐selective agonists stimulated adenylyl cyclase activity in the cells, although cyclase activity was stimulated by forskolin, carbachol, and vasoactive intestinal peptide. DMPP‐stimulated Ca2+ uptake was inhibited by both D1‐ and D2‐selective dopamine agonists. PCR analysis was used to determine which of the dopamine receptor subtypes within the D1‐like and D2‐like subfamilies was responsible for the observed inhibition. PCR analysis indicated that mRNA for only D4 and D5 dopamine receptor subtypes was present in chromaffin cells. These combined data suggest that D1‐ and D2‐selective agonists inhibit Ca2+ uptake and catecholamine secretion by activating D4 and D5 dopamine receptors on chromaffin cells.</description><subject>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology</subject><subject>Adenylate Cyclase Toxin</subject><subject>Adenylyl cyclase</subject><subject>Adenylyl Cyclases - metabolism</subject><subject>Adrenal gland</subject><subject>Adrenal Medulla - drug effects</subject><subject>Adrenal Medulla - metabolism</subject><subject>Adrenals. Interrenals</subject><subject>Adrenomedullary hormones. Regulation</subject><subject>Animals</subject><subject>Base Sequence</subject><subject>Benzazepines - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Bromocriptine - pharmacology</subject><subject>Ca2+ uptake</subject><subject>Calcium - physiology</subject><subject>Catecholamines - metabolism</subject><subject>Cattle</subject><subject>Cells, Cultured</subject><subject>Colforsin - pharmacology</subject><subject>Cyclic AMP - physiology</subject><subject>Depression, Chemical</subject><subject>Dimethylphenylpiperazinium Iodide - antagonists & inhibitors</subject><subject>Dopamine - physiology</subject><subject>Dopamine Agonists - pharmacology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Molecular Sequence Data</subject><subject>PCR</subject><subject>Pertussis Toxin</subject><subject>Polymerase Chain Reaction</subject><subject>Potassium - antagonists & inhibitors</subject><subject>Receptors, Dopamine - drug effects</subject><subject>Receptors, Dopamine - genetics</subject><subject>Receptors, Dopamine - physiology</subject><subject>Receptors, Dopamine D1 - physiology</subject><subject>Receptors, Dopamine D2 - physiology</subject><subject>Receptors, Dopamine D4</subject><subject>Receptors, Dopamine D5</subject><subject>Second Messenger Systems - drug effects</subject><subject>Veratridine - antagonists & inhibitors</subject><subject>Vertebrates: endocrinology</subject><subject>Virulence Factors, Bordetella - pharmacology</subject><issn>0022-3042</issn><issn>1471-4159</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkV2PEyEUhonRrHX1J5iQaLyb8cAAA3plputas2rixzWhDFia-agw1e2f8DdLtx_xzpgQSM778h44D0LPCJQEmHi5LgmrScEIVyVRSpRCAAFKaXl7D83O2n00g1wtKmD0IXqU0hqACCbIBbqQnFLF5Qz9no8b04fBxe_B4sWwCsswhXHAo8eNmZxdjd2djr84G92d5OPY42aVd-N9GHDjui69wlc_Q-sG6_C0MtPfUYuEP7g25LQWL3d4zrAZWjzn-NQbf3bWbaYxpsfogTddck-O5yX69vbqa_OuuPl0vWje3BSWMaAFrQwBwa3N43BWeMV9ToCla4G3layINFBLlodDGCiQlktfMStaKiXI2laX6MUhdxPHH1uXJt2HZPM_zODGbdJ1rSiTTP3TSGqglVI0G18fjDaOKUXn9SaG3sSdJqD32PRa79HoPRq9x6ZP2PRtvv302Ga77F17vnvklPXnR90kazofzWBDOtuoEpTXJNuuD7ZfoXO7_3mBfv-xyetUqP4AKPG1KA</recordid><startdate>199601</startdate><enddate>199601</enddate><creator>Dahmer, Mary K.</creator><creator>Senogles, Susan E.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>199601</creationdate><title>Dopaminergic Inhibition of Catecholamine Secretion from Chromaffin Cells: Evidence that Inhibition Is Mediated by D4 and D5 Dopamine Receptors</title><author>Dahmer, Mary K. ; Senogles, Susan E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4402-23a1065cc046ec6f95fece0bed05d38318a0784199140908c58f34c6d288087c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology</topic><topic>Adenylate Cyclase Toxin</topic><topic>Adenylyl cyclase</topic><topic>Adenylyl Cyclases - metabolism</topic><topic>Adrenal gland</topic><topic>Adrenal Medulla - drug effects</topic><topic>Adrenal Medulla - metabolism</topic><topic>Adrenals. Interrenals</topic><topic>Adrenomedullary hormones. Regulation</topic><topic>Animals</topic><topic>Base Sequence</topic><topic>Benzazepines - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Bromocriptine - pharmacology</topic><topic>Ca2+ uptake</topic><topic>Calcium - physiology</topic><topic>Catecholamines - metabolism</topic><topic>Cattle</topic><topic>Cells, Cultured</topic><topic>Colforsin - pharmacology</topic><topic>Cyclic AMP - physiology</topic><topic>Depression, Chemical</topic><topic>Dimethylphenylpiperazinium Iodide - antagonists & inhibitors</topic><topic>Dopamine - physiology</topic><topic>Dopamine Agonists - pharmacology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Molecular Sequence Data</topic><topic>PCR</topic><topic>Pertussis Toxin</topic><topic>Polymerase Chain Reaction</topic><topic>Potassium - antagonists & inhibitors</topic><topic>Receptors, Dopamine - drug effects</topic><topic>Receptors, Dopamine - genetics</topic><topic>Receptors, Dopamine - physiology</topic><topic>Receptors, Dopamine D1 - physiology</topic><topic>Receptors, Dopamine D2 - physiology</topic><topic>Receptors, Dopamine D4</topic><topic>Receptors, Dopamine D5</topic><topic>Second Messenger Systems - drug effects</topic><topic>Veratridine - antagonists & inhibitors</topic><topic>Vertebrates: endocrinology</topic><topic>Virulence Factors, Bordetella - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dahmer, Mary K.</creatorcontrib><creatorcontrib>Senogles, Susan E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dahmer, Mary K.</au><au>Senogles, Susan E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dopaminergic Inhibition of Catecholamine Secretion from Chromaffin Cells: Evidence that Inhibition Is Mediated by D4 and D5 Dopamine Receptors</atitle><jtitle>Journal of neurochemistry</jtitle><addtitle>J Neurochem</addtitle><date>1996-01</date><risdate>1996</risdate><volume>66</volume><issue>1</issue><spage>222</spage><epage>232</epage><pages>222-232</pages><issn>0022-3042</issn><eissn>1471-4159</eissn><coden>JONRA9</coden><abstract>: Previous studies have suggested that activation of D2‐like dopamine receptors inhibits catecholamine secretion from adrenal chromaffin cells. The purpose of this study was to determine whether the activation of D1‐like receptors on chromaffin cells affects either catecholamine release from the cells or the inhibition of secretion by D2‐like dopamine receptors. Both D1‐ and D2‐selective agonists inhibited secretion elicited by dimethylphenylpiperazinium (DMPP), veratridine, and high K+ levels. The D1‐selective agonists 6‐chloro‐7,8‐dihydroxy‐3‐allyl‐1‐phenyl‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine (Cl‐APB) and SKF‐38393 inhibited DMPP‐stimulated catecholamine secretion in a concentration‐dependent manner; 50% inhibition was obtained with ∼10 µM Cl‐APB and ∼100 µM SKF‐38393. Of the D2‐selective agonists, bromocriptine was a more potent inhibitor of DMPP‐stimulated catecholamine release than was quinpirole. The inhibition of secretion caused by Cl‐APB or SKF‐38393 was additive with the inhibition caused by bromocriptine. Pertussis toxin treatment (50 ng/ml, 18 h) attenuated the inhibitory effect of D2‐selective, but not D1‐selective, dopamine agonists. In addition, forskolin‐stimulated adenylyl cyclase activity was inhibited by D2‐selective, but not D1‐selective, agonists. Neither D1‐ nor D2‐selective agonists stimulated adenylyl cyclase activity in the cells, although cyclase activity was stimulated by forskolin, carbachol, and vasoactive intestinal peptide. DMPP‐stimulated Ca2+ uptake was inhibited by both D1‐ and D2‐selective dopamine agonists. PCR analysis was used to determine which of the dopamine receptor subtypes within the D1‐like and D2‐like subfamilies was responsible for the observed inhibition. PCR analysis indicated that mRNA for only D4 and D5 dopamine receptor subtypes was present in chromaffin cells. These combined data suggest that D1‐ and D2‐selective agonists inhibit Ca2+ uptake and catecholamine secretion by activating D4 and D5 dopamine receptors on chromaffin cells.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>8522958</pmid><doi>10.1046/j.1471-4159.1996.66010222.x</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3042 |
ispartof | Journal of neurochemistry, 1996-01, Vol.66 (1), p.222-232 |
issn | 0022-3042 1471-4159 |
language | eng |
recordid | cdi_proquest_miscellaneous_77924849 |
source | MEDLINE; Wiley Journals |
subjects | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology Adenylate Cyclase Toxin Adenylyl cyclase Adenylyl Cyclases - metabolism Adrenal gland Adrenal Medulla - drug effects Adrenal Medulla - metabolism Adrenals. Interrenals Adrenomedullary hormones. Regulation Animals Base Sequence Benzazepines - pharmacology Biological and medical sciences Bromocriptine - pharmacology Ca2+ uptake Calcium - physiology Catecholamines - metabolism Cattle Cells, Cultured Colforsin - pharmacology Cyclic AMP - physiology Depression, Chemical Dimethylphenylpiperazinium Iodide - antagonists & inhibitors Dopamine - physiology Dopamine Agonists - pharmacology Fundamental and applied biological sciences. Psychology Molecular Sequence Data PCR Pertussis Toxin Polymerase Chain Reaction Potassium - antagonists & inhibitors Receptors, Dopamine - drug effects Receptors, Dopamine - genetics Receptors, Dopamine - physiology Receptors, Dopamine D1 - physiology Receptors, Dopamine D2 - physiology Receptors, Dopamine D4 Receptors, Dopamine D5 Second Messenger Systems - drug effects Veratridine - antagonists & inhibitors Vertebrates: endocrinology Virulence Factors, Bordetella - pharmacology |
title | Dopaminergic Inhibition of Catecholamine Secretion from Chromaffin Cells: Evidence that Inhibition Is Mediated by D4 and D5 Dopamine Receptors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T08%3A26%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dopaminergic%20Inhibition%20of%20Catecholamine%20Secretion%20from%20Chromaffin%20Cells:%20Evidence%20that%20Inhibition%20Is%20Mediated%20by%20D4%20and%20D5%20Dopamine%20Receptors&rft.jtitle=Journal%20of%20neurochemistry&rft.au=Dahmer,%20Mary%20K.&rft.date=1996-01&rft.volume=66&rft.issue=1&rft.spage=222&rft.epage=232&rft.pages=222-232&rft.issn=0022-3042&rft.eissn=1471-4159&rft.coden=JONRA9&rft_id=info:doi/10.1046/j.1471-4159.1996.66010222.x&rft_dat=%3Cproquest_cross%3E17023992%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17023992&rft_id=info:pmid/8522958&rfr_iscdi=true |